CA
NZ
UK
AU
IND
US
Atrium is the only name with a same-week financing. Atrium Therapeutics (NASDAQ:RNA) was down 3.15% in premarket trading on October 9, 2026 on a listed price of USD 8.26. On October 8 the company announced a privatePlacementof about USD 50 million: 5,170,384 shares at …
Humana (NYSE:HUM) was indicated up 14.82% in the October 9, 2026 premarket session, based on a listed price of USD 387.12 on the premarket screener. Published reports tie the move to the Centers for Medicare and Medicaid Services 2027 Star Ratings, released on October …
Pfizer (NYSE:PFE) said the FDA approved Tukysa, known generically as tucatinib, as first-line maintenance treatment in HER2-positive breast cancer. The supporting figure is progression-free survival of 24.9 months versus 16.3 months, an 8.6-month gap by simple arithmetic on two published numbers. Progression-free survival measures …
Alignment Healthcare (NASDAQ:ALHC) was indicated down 23.08% in the October 9, 2026 premarket session, based on a listed price of USD 8.71 and a market value near USD 1.81 billion on the screener. Published reports link the drop to the Centers for Medicare and …
Aclarion, Inc. (NASDAQ:ACON), a healthcare technology company focused on diagnosing chronic low back pain, said it broadened the enrollment criteria for its pivotal CLARITY trial after enrollment lagged under the original, more narrowly defined criteria. The revised criteria have now been approved at nine …
ADC Therapeutics SA (NYSE:ADCT), a Swiss biotech focused on antibody-drug conjugates for blood cancers, announced a comprehensive financial restructuring. The package includes an $86.6 million privatePlacementwith new and existing institutional investors, an amendment removing a $150 million change-of-control payment from itsRoyaltyfinancing agreement, and aLoanamendment …
argenx SE (NASDAQ:ARGX), an Amsterdam-based immunology company best known for its approved drug VYVGART, announced it will discontinue its Phase 3 UNITY study of efgartigimod in Sjögren's disease. An independent data monitoring committee recommended halting the trial after an interim analysis found it unlikely …
Biofrontera Inc. (NASDAQ:BFRI), a dermatology-focused biopharmaceutical company, filed a supplemental application with the FDA to expand use of its approved skin treatment, Ameluz, combined with red light therapy, to cover actinic keratoses on the arms, legs, neck, and trunk, not just the face and …
Bristol-Myers Squibb Company (NYSE:BMY), a global biopharmaceutical company with a broad oncology and immunology portfolio, announced topline results from its Phase 3 EXCALIBER-RRMM study. The trial tested ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone against a standard three-drug regimen in 800 patients with …
China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC), a Chinese company focused on traditional Chinese medicine products, entered a definitive agreement to sell 8 million shares at $1.50 per share in a registered direct offering, alongside matching warrants. Expected gross proceeds are approximately $12 million before fees. …
Please wait processing your request...